Literature DB >> 1763405

[Simultaneous radiotherapy and chemotherapy with cisplatin and 5-fluorouracil in advanced head and neck tumors].

R Fietkau1, H Iro, G G Grabenbauer, A Altendorf-Hofmann, R Sauer.   

Abstract

Between 1.1. 1987 and 31.12. 1988 47 patients with locally advanced head- and neck tumours (UICC-stage II: one patient, stage III: 16 patients, stage IV: 30 patients) were treated with simultaneous radio-chemotherapy. Localisations were hypopharynx (23 = 49%), oropharynx (16 = 34%) and other sites (8 = 17%). Radiation therapy consisted of 60 Gy (primary region, N+) or 50 Gy (N0) in daily fractions of 2 Gy each over six weeks. During week 1 and 5 of radiotherapy two courses of chemotherapy with 5-FU (600 mg/m2/day, i.v. continuous infusion for five days) and cis-platin (25 mg/m2/day i.v. bolus for five days) were administered. 43/47 patients (91%) responded to therapy. 34/47 (72%) patients achieved a complete remission, 9/47 (19%) a partial remission, and 4/47 (9%) no change. With a minimum follow-up of 26 months 17/47 patients (36%) are alive and NED, 4/47 (9%) are alive with tumour. 18 patients (38%) died of cancer, eight patients (17%) died of second tumours, intercurrent diseases and of unknown reasons. Actuarial four-year survival is 45% (stage III: 56%, stage IV: 42%), four-year NED survival is 35% (stage III: 68%, stage IV: 18%). There were no loco-regional recurrences after additional surgical treatment of the primary and the neck following complete remission. In contrast after RCT alone and complete remission local recurrences in 6/21 patients (29%) and regional recurrences in 5/24 patients (21%) occurred. We conclude that simultaneous RCT is a new very effective treatment modality of locally advanced head and neck tumours producing superior loco-regional control compared to conventional management.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1763405

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  7 in total

Review 1.  [Concurrent radiochemotherapy for the treatment of solid tumors].

Authors:  R Fietkau
Journal:  Strahlenther Onkol       Date:  2012-11       Impact factor: 3.621

2.  [A phase-I/II study on the local hyperthermia of cervical N2/N3 lymph node metastases].

Authors:  H Stahl; P Wust; R Graf; J Löffel; J Bier; H Riess; V Jahnke; R Felix
Journal:  Strahlenther Onkol       Date:  1997-04       Impact factor: 3.621

3.  Feasibility of 6-month maintenance cetuximab after adjuvant concurrent chemoradiation plus cetuximab in squamous cell carcinoma of the head and neck.

Authors:  C Matuschek; E Bölke; C Belka; U Ganswindt; M Henke; P Stegmaier; M Bamberg; S Welz; J Debus; A Gioules; A Voigt; G Volk; C Ohmann; T Wiegel; V Budach; M Stuschke; J Schipper; P A Gerber; W Budach
Journal:  Strahlenther Onkol       Date:  2013-07-05       Impact factor: 3.621

4.  [Principles of radiation therapy for malignant tumors of the orbit and the periorbital area].

Authors:  T Kuhnt; M Janich
Journal:  HNO       Date:  2010-01       Impact factor: 1.284

5.  Outcome and histopathologic regression in oral squamous cell carcinoma after preoperative radiochemotherapy.

Authors:  Oliver Driemel; Tobias Ettl; Oliver Kölbl; Torsten E Reichert; Bernd V Dresp; Jürgen Reuther; Hans Pistner
Journal:  Strahlenther Onkol       Date:  2009-05-15       Impact factor: 3.621

6.  The influence of supportive nutritional therapy via percutaneous endoscopically guided gastrostomy on the quality of life of cancer patients.

Authors:  M Senft; R Fietkau; H Iro; D Sailer; R Sauer
Journal:  Support Care Cancer       Date:  1993-09       Impact factor: 3.603

7.  [Predictive significance of reflex otalgia in local radical radiotherapy of oropharyngeal carcinomas].

Authors:  K T Beer; C von Briel; T Lampret; S Marré; D Vetterli; P Zbären; R H Greiner
Journal:  Strahlenther Onkol       Date:  1998-06       Impact factor: 3.621

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.